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ABSTRACT 
OBJECTIVE 
 The purpose of the study was to evaluate the effect of occupational therapy 
intervention in insomnia among people with anxiety. 
METHODS 
Totally 30 subjects, 15 in experimental group and 15 in control group with age 
of 20 to 45 years participated in current study. 
RESULTS 
The mean of post-test was found to be 96 (control) and 62.93 (experimental) 
respectively. The calculated‘t’ value was obtained to be 3.785 with level of 
significance 0.05.Statistical significance is present in experimental group than control 
group with regard to effect of occupational therapy intervention with conventional 
therapy. 
CONCLUSION 
Occupational therapy intervention has statistically significant effect on the 
reduction of Insomnia.  
KEY WORDS 
Insomnia, Anxiety, Occupational therapy intervention. 
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INTRODUCTION 
Insomnia is a serious health concern which result in poor day time functioning 
and work performance, people with insomnia have more medical problems than 
people without insomnia29.The causes of sleep loss are multifactorial and it fall under 
two major, somewhat overlapping categories: lifestyle or occupational such as shift 
work, prolonged working hours, irregular sleep schedules, and sleep disorders such as 
Breathing-Related Sleep Disorders, narcolepsy, circadian rhythm disorders, Restless 
Leg Syndrome. Unfortunately, available epidemiological data are not sufficient to 
determine the extent to which sleep loss is caused by pathology versus behavioural 
components. 
In the past years research has overturned the dogma that sleep loss has no 
health effects, apart from daytime sleepiness. Studies suggest that sleep loss may have 
wide-range of effects on the cardiovascular, endocrine, immune, and nervous systems, 
including Obesity in adults and children, Diabetes and impaired glucose tolerance, 
Anxiety symptoms, depressed mood andalcohol use, Even insomnia is associated with 
suicidal ideation among patients with depression, alcohol misuse or dependence, and 
posttraumatic stress disorder. The link between insomnia and suicide is evident across 
the life span, including adolescents and older adulthood. 
Estimates of insomnia prevalence have varied widely, from 10% to 40%.  
According to National Institutes of Health 2005, insomnia has a prevalence of 10% if 
the definition necessitates daytime distress or impairment, given all the information 
available, the prevalence of insomnia symptoms may be estimated at 30% and 
specific insomnia disorders at 5% to 10%. 
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Sleep is an essential aspect of daily life for which occupational therapy 
services may be warranted, and there is a great need to expand the profession’s 
understanding of sleep-related interventions13.As an Occupational therapy practitioner 
it is important to analyse the day time consequence of Insomnia that include, Daytime 
sleepiness, fatigue, depressed mood, lack of energy, impaired cognition, memory 
problems, irritability, psychomotor dysfunction, and decreased alertness and 
concentration. These consequences affect overall Activities of daily living (ADL) and 
productivity of an individual. ADL and productivity are the important areas of 
occupational therapy practice.  
Cognitive behavioural therapy for insomnia (CBT-I) is effective at reducing 
insomnia symptom severity,including in populations with comorbid conditions. The 
underpinnings of CBT-I flow from the application of both operant and classical 
conditioning paradigms in the form of stimulus control instruction, the focus on sleep-
interfering behaviours in the form of sleep hygiene, the recognition of and focus on 
reducing the hyperarousal features of insomnia. 
Even though there is a large population is suffering from the consequences of 
insomnia which directly affects the daily life and work performance of an individual, 
very less occupational therapy practitioner address these problems. As an 
occupational therapy practitioner it is important to have a deep understanding of sleep 
and sleep related problems hence this study has been initiated. 
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OPERATIONAL DEFINITION 
INSOMNIA:  
“An insomnia disorder is defined as a subjective report of difficulty with sleep 
initiation, duration, consolidation, or quality that occurs despite adequate opportunity 
for sleep, and that result in some form of daytime impairment”. 
ANXIETY: 
Anxiety is an emotion characterized by feelings of tension, worried thoughts, 
distributed sleep and physical changes like increased blood pressure. People with 
anxiety disorders usually have intrusive thoughts and concerns. They avoid certain 
situations out of worry. 
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NEED OF THE STUDY 
 The consequences of poor sleep are multifaceted and can result in decreased 
academic and work performance. Even though sleep is an essential aspect of daily 
living there are less research happened in occupational therapy servicerelated to sleep. 
So there is a need to explore the significance of occupational therapy intervention in 
sleep.  
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AIM & OBJECTIVES 
AIM 
The aim of the study is to find out the effect of occupational therapy 
interventions in insomnia among person with anxiety. 
OBJECTIVES 
 To assess the level of insomnia among person with anxiety. 
 To evaluate the effect of occupational therapy intervention in Insomnia. 
 To compare the effect of conventional therapy and occupational therapy 
techniques. 
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HYPOTHESIS 
ALTERNATE HYPOTHESIS 
 Occupational therapy technique will have a significant effect on insomnia. 
NULL HYPOTHESIS 
 Occupational therapy technique will have no significant effect on insomnia.     
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RELATED LITERATURE 
PHYSIOLOGY OF SLEEP/WAKE TRANSITION: 
 By definition, sleep is the alternate condition of wakefulness47 the state of 
wakefulness is primarily driven by the activity of specific cell groups of the ascending 
reticular arousal system (ARAS) located in the brainstem. The Ascending Reticular 
Activating System is composed by two branches (Figure 1). The first originates from 
the acetylcholine nuclei (i.e. the pedunculo-pontine and laterodorsal tegmental nuclei) 
and innervates the thalamocortical neurons, whereas the second originates from 
monoaminergic and glutamatergic cell groups in the brainstem, bypasses the 
thalamus, and activates neurons in the lateral hypothalamic area and basal forebrain59. 
 
 
 
 
 
Figure 1: Cholinergic neurons innervate the thalamus, whereas monoaminergic 
and glutamatergic neurons extended to the hypothalamus, basal forebrain, and 
cerebral cortex. The orexin neurons in the lateral hypothalamus indirectly 
reinforce the brainstem arousal pathways and directly excite the cerebral cortex 
and basal forebrain. Basal forebrain (BF) : Gamma-Amino Butyric 
Acid(GABA), Ach: acetylcholine); raphe:, dorsal raphe nucleus (5-HT: 
serotonin); LC: locus coeruleus (NA: norepinephrine); LDT: laterodorsal 
tegmental nucleus (Ach); LH: lateral hypothalamus (ORX: Orexin; MCH: 
melanin-concentrating hormone), PPT: pedunculopontine tegmental nucleus 
(Ach); TMN: tuberomammillary nucleus (His: histamine); vPAG: ventral 
periaqueductal gray (DA: dopamine). (adapted from Saper, et al.59). 
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Wakefulness is further promoted by the orexin/hypocretin neurons in the 
lateral hypothalamus and the acetylcholine neurons of the basal nuclei. 
Sleep, however, as correctly identified 80 years ago by Von Economo65, is 
promoted by neurons in the lateral hypothalamus. More specifically, neurons in the 
ventral lateral preoptic area (VLPO) inhibit the monoaminergic cell groups in the 
hypothalamus and brainstem using galanin and Gamma-Amino Butyric Acid 
neurotransmitters. However, during the wake state, theVentral Lateral Preoptic Area 
neurons are themselves inhibited by the Ascending Reticular Arousal System 
(ARAS). This reciprocal inhibitory state has been called the “flip-flop” switch59, 
which allows the rapid transition from a wake condition to a sleep state and vice 
versa. Thus, the sleep/wake transition is regulated by two mutual inhibition systems 
that cyclically suppress each other. 
These systems seem to be hierarchically influenced by both the homeostatic 
and the circadian regulation of sleep59, which constitute the basis of the two-process 
model of sleep regulation18.According to this model, the sleep-wake alternation 
depends on a sleep-dependent homeostatic process and a sleep-independent circadian 
process. The homeostatic drive depends on the previous waking time: the propensity 
to sleep increases during wake and dissipates during sleep. The circadian process is 
independent of the sleep pressure and modulates sleep pressure as a function of 
exogenous (e.g. light) and endogenous rhythms (e.g. biological clock). Sleep is then 
the result of the interaction between these two processes. 
This model has provided accurate predictions regarding wake and sleep 
behaviour in different experimental setting and in free-living environments14. 
Recently adenosine, a by-product of brain energy metabolism (i.e. the final results of 
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a double ATP breakdown) has been proposed as the physiological accumulator of the 
need for sleep54.  During wakefulness, adenosine accumulates in the basal forebrain as 
a consequence of ATP consumption, whereas during sleep its levels decrease in the 
cortex, basal forebrain, hypothalamus, and brainstem17.  It has been hypothesized that 
slow wave activity is the physiological marker of this adenosine down-regulation43. 
Adenosine seems to disinhibit the ventral lateral preoptic area neurons, and inhibits 
hypocretin or orexin and the basal forebrain neurons.17 Interestingly, caffeine is as an 
adenosine receptor antagonist, caffeine prevents sleep by binding to adenosine 
receptors. 
SLEEP ARCHITECTURE: 
Sleep is not a unique phenomenon, but a structured sequence of events that 
follows a regular, cyclic program. It is organized in different phases (or stages), each 
one characterized by a specific pattern of tonic and phasic physiological activity. 
Sleep is composed of two principal states, namely Non-rapid eye movement (NREM) 
or Synchronized sleep and Rapid eye movement (REM), also called desynchronized 
sleep or paradoxical sleep. These two sleep states cyclically alternate during sleep 
depending on several factors such as, time of day, temperature, sleep pressure, and 
environmental conditions. Non-rapid eye movement sleep is further divided in three 
stages (N1, N2, N3 or slow wave sleep, SWS) according to the amplitude and 
frequency of the electroencephalographic (EEG) activity. 
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Figure 2 
During nocturnal sleep there are 4-6 cyclical alternations of non-rapid eye 
movement and rapid eye movement phases. In the first cycle, sleep onset usually 
occurs in N1 sleep which is followed by N2 and then SWS. Afterwards, sleep 
typically becomes lighter, with a brief period of N2 or N1 preceding the onset of rapid 
eye movement. The end of rapid eye movement is indicated by a short awakening 
from sleep and/or a body movement or a transition back to N2 sleep. Each sleep cycle 
lasts 90-110 minutes and differs from the others. N1 sleep usually occurs at sleep 
onset and as a transitional state across the night, representing about 2 to 5 % of 
nocturnal sleep. N2 sleep is the more stable stage, occurring constantly through the 
night and constituting about 45 to 55 % of sleep. SWS, which represent about 20 to 25 
% of total nocturnal sleep, is predominant in the first half of the night, often occurring 
only in the first two cycles. On the other hand, the first rapid eye movement  episode 
is usually short (1-5 min) but then becomes longer across cycles, becoming 
predominant in the second half of the night, amounting to 20-25% of the sleep.22 
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INSOMNIA: 
Insomnia is the most common sleep disorder which affects about 10–15% of 
the populationand is defined as difficulty in falling asleep, maintaining sleep or non-
restorative sleep (American Academy of Sleep Medicine, 2005; American Psychiatric 
Association, 2000). In addition to nocturnal symptoms, daytime consequences are 
frequently reported by insomniacs, in particular, increased daytime sleepiness, 
fatigue, mood disturbance, exhaustion, dysphoria which generates significant distress 
(American Academy of Sleep Medicine, 2005), functional and cognitive impairment 
and reduced quality of life. 
The core symptoms of insomnia, specified in major disease and sleep disorder 
classification manuals (ICSD-3, 2014; DSM-V, 2013; ICD-10, 1992), correspond to 
difficulties with initiating and/or maintaining sleep, or non-restorative sleep (i.e. poor 
quality sleep). To achieve disorder ‘status’, sleep disturbance must not be simply a 
function of restricted sleep opportunity (i.e. curtailment), or environmental 
perturbation (such as noise, bed partner snoring etc.). Importantly, the diagnosis of 
insomnia disorder is made only when impairment in daytime functioning is present, 
which is linked (attributionally) to night-time sleep difficulties. Daytime impairments 
may be measured with reference to isolated symptoms, such as fatigue and but also to 
more global dysfunction; for example, in areas of social and occupational functioning 
(DSM-V, 2013). One additional marker of insomnia severity refers to the frequency 
and length (persistence) of insomnia symptoms, which, for an insomnia diagnosis, is 
usually set at greater than or equal to three nights per week, being present for at least a 
one month period. 
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It has been shown that insomnia is linked with absenteeism (at least twice in 
workers with insomnia than workers without insomnia,37 accidents,decreased 
productivity and efficiency at work and decreased job satisfaction. 41 
Epidemiological data suggest that about one-third of the general population 
suffer from symptoms of insomnia,52 with literature showing a prevalence ranging 
from 5% to 40% depending on different definitions. When consensus criteria are 
applied, the reported prevalence is between 20% and 25% of adults.52 Primary 
insomnia, which is an insomnia not due to other medical conditions or sleep disorders, 
seems to account for 3% of those diagnosed with insomnia. Insomnia is more 
prevalent in females than males and symptoms of insomnia increase with aging.62 
Insomnia is a very common sleep disorder already in early adulthood, with incidence 
remaining stable across adulthood.  
Furthermore, insomnia is associated with depression and anxiety48and seems 
to be associated with an increased risk for cardiovascular diseases. In addition, it has 
been observed an association between insomnia and mortality. Other evidence 
reported elevated heart rate and altered heart rate variability (HRV) in insomnia 
patients that are known to be risk factors for cardiovascular disease and mortality.35 
Although the pathogenesis of primary insomnia is still unknown, nocturnal 
symptoms as well as diurnal complaints in insomniacs may be attributable to a 
chronic state of hyperarousal, i.e. a condition of elevated physiological activation that 
affects somatic, cortical, and cognitive functioning throughout the day as well as at 
night, leading to nocturnal and diurnal symptoms. 
Indeed, night time and daytime studies of insomniacs show decreased 
nocturnal production of melatoni, high levels of cortisol and ACTH, increased body 
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metabolic rate, basal temperature, heart, blood pressure, muscular tone and 
electrodermal activity; decreased pre-ejection period, elevated high frequency EEG 
activity in both rapid eye movement and non-rapid eye movement sleep, abnormal 
intracortical excitability, and increased subjective perception of hyperarousal as 
assessed by questionnaires.55 
Pharmacotherapy 
A number of pharmacological agents exists for the treatment of insomnia 
symptoms, most of which primarily work via their agonistic effects on gamma-
aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central 
nervous system (CNS). Specifically, the most common class of hypnotics, 
benzodiazepines (e.g. temazepam), and the newer non-benzodiazepine receptor 
agonists (zolpidem, eszopiclone; BZRAs or ‘z drugs’) modulate GABAA receptors, 
facilitating the inhibitory effects of gamma-aminobutyric acid on overall CNS 
arousal, while similarly inhibiting norepinephrine activity. Benzodiazepine receptor 
agonists are considered more effective due to their greater selectivity for the alpha 1 
sub-unit, thus enhancing activity in terms of sedation and limiting more generic 
effects involved in the interaction with other subunits (Nutt & Stahl, in press). These 
compounds also tend to have shorter half-lives than the original benzodiazepines, 
reducing the likelihood of carry-over effects the next day; though available data on 
side-effects and comparable efficacy do not allow for clear conclusions to be made.31 
Although demonstrating effectiveness (moderate to large effects) in terms of 
improving major indicators of sleep continuity and quality in those with insomnia, 
positive effects of Benzodiazepine receptor agonists have yet to be reliably 
demonstrated beyond active administration. Indeed, as it stands, there is not enough 
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evidence to suggest or recommend that Benzodiazepine receptor agonists are useful 
for the long-term management of chronic insomnia beyond four weeks of treatment 
(NIH state-of-the-science conference statement, 2005). Some recent studies report 
improvements during extended/intermittent use of hypnotics over 6 and 12 month 
periods but again no adequate data exist indicating maintained benefits long after 
treatment cessation. Concerns about long-term hazardous side-effects and tolerance 
issues strongly argue against long-term prescription: safety and efficacy must be 
documented. 
Cognitive Behavioural Therapy for Insomnia (CBT-I) 
Given that maladaptive behaviours and cognitive processes are thought to 
underlie the maintenance of insomnia, it is intuitive that therapy targets these factors 
directly.58 Cognitive behavioural therapy for insomnia (CBT-I) is an evidence-based 
treatment modality, containing a number of supported techniques to improve sleep. 
Practice parameters set out by the American Academy of Sleep Medicine (AASM) 
recommend and endorse the following single components: paradoxical intention 
therapy, stimulus control therapy, sleep restriction therapy, progressive muscular 
relaxation, and biofeedback.25 In addition, two multicomponent CBT approaches are 
also supported. Indeed, most outcome research has focused on multi-component, 
multisession CBT interventions 
Combination therapy: 
Combination therapy involves prescribing both cognitive behavioural therapy 
for insomnia (CBT-I) and a medication, usually for six to eight weeks.The medication 
is then tapered off or to an as-needed schedule, while continuing the CBT-I. 
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Taken together, the evidence indicates that CBT-I alone, drug therapy alone, 
and combination therapy all improve measures of insomnia (eg, wake time after sleep 
onset) within weeks of initiating the therapy. Continuing CBT-I alone after the 
completion of initial therapy appears to be the best option for maintaining 
improvement long-term. CBT-I also increases the likelihood that the medication can 
eventually be tapered. If sleep restriction therapy is combined with hypnotic 
medication, clinicians should be aware that the combination of chronic partial sleep 
deprivation and medication hangover could significantly increase daytime sleepiness 
and behavioural risk. The evidence is insufficient to justify combination therapy as 
routine initial management for insomnia patients. Many patients will improve with 
CBT-I alone, without pharmacologic therapy. 
Follow-up 
 If the treatment is successful, patients will report both improved sleep at night 
and improvement of daytime deficits. Discontinuation of the medication should be 
considered in any patient who is receiving pharmacologic therapy alone or 
combination therapy. 
Patients who have little improvement during the initial trial of cognitive 
behavioural therapy, pharmacologic therapy, or combination therapy may have other 
causes of poor sleep. Adherence with the prescribed therapy should be confirmed and 
then additional diagnostic evaluation performed. 
GENERALIZED ANXIETY DISORDER:  
GAD often presents through hyper-vigilance, excessive worrying, muscle 
tension, irritability, fatigue, and restlessness. These key features are difficult for the 
 16 
patients to manage and control, keeping them from completing daily tasks (American 
Psychiatric Association, 2013). To be diagnosed with generalized anxiety disorder 
through the DSM-V, a person must exhibit three or more of the six symptoms listed in 
the DSM those are 
A. Excessive anxiety and worry (apprehensive expectation), occurring more days 
than not for at least 6 months, about a number of events or activities (such as 
work or school performance). 
B. The individual finds it difficult to control the worry. 
C. The anxiety and worry are associated with three (or more) of the following six 
symptoms (with at least some symptoms having been present for more days than 
not for the past 6 months); Note: Only one item is required in children. 
1. Restlessness or feeling keyed up or on edge. 
2. Being easily fatigued. 
3. Difficulty concentrating or mind going blank. 
4. Irritability. 
5. Muscle tension. 
6. Sleep disturbance (difficulty falling or staying asleep, or restless, 
unsatisfying sleep). 
D. The anxiety, worry, or physical symptoms cause clinically significant distress or 
impairment in social, occupational, or other important areas of functioning. 
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E. The disturbance is not attributable to the physiological effects of a substance 
(e.g., a drug of abuse, a medication) or another medical condition (e.g., 
hyperthyroidism). 
F. The disturbance is not better explained by another mental disorder (e.g., anxiety 
or worry about having panic attacks in panic disorder, negative evaluation in 
social anxiety disorder [social phobia], contamination or other obsessions in 
obsessive-compulsive disorder, separation from attachment figures in separation 
anxiety disorder, reminders of traumatic events in posttraumatic stress disorder, 
gaining weight in anorexia nervosa, physical complaints in somatic symptom 
disorder, perceived appearance flaws in body dysmorphic disorder, having a 
serious illness in illness anxiety disorder, or the content of delusional beliefs in 
schizophrenia or delusional disorder). 
Causes of Generalized Anxiety Disorder (GAD) 
It is thought differences in the following neurotransmitters play a role in 
causing GAD: 
 Serotonin 
 Dopamine 
 Norepinephrine 
 Gamma-aminobutyric acid (GABA) 
It is these chemicals that are altered by antidepressants, some of which are 
effective treatments for generalized anxiety disorder. Abnormal levels of other 
chemicals, like peptides and hormones, may also partially cause generalized anxiety 
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disorder. MRI scans have revealed that some structures of the brain are changed in 
some anxiety disorders.Impaired cognitive functioning also appears to be tied to 
generalize anxiety disorder in both children and adults. It may also as a result of the 
following. 
 Early traumatic experiences such as a parent's death 
 Chronic experiences of fear 
 Chronic feelings of helplessness 
 Abnormal hormones, possibly due to stress, prenatally 
Pharmacotherapy: 
Antidepressants, particularly the selective serotonin reuptake inhibitors 
(SSRIs), are widely used to treat and prevent a variety of anxiety disorders. Examples 
of SSRIs that are commonly used to treat chronic anxiety include citalopram (Celexa), 
escitalopram (Lexapro), fluoxetine (Prozac), paroxetine (Paxil), and sertraline 
(Zoloft). The antidepressants duloxetine (Cymbalta) and venlafaxine (Effexor), SNRIs 
(serotonin and norepinephrine reuptake inhibitors) which act on the brain chemicals 
serotonin and norephinephrine, and some of the tricyclic antidepressants like 
imipramine (Tofranil), may also help. Antihistamines (such as hydroxyzine) and beta-
blockers (such as propranolol) can help mild cases of anxiety as well as performance 
anxiety, a type of social anxiety disorder. Antidepressants such as SSRIs or SNRIs or 
tricyclics need to be taken daily whether or not anxiety has on that particular day. 
Antihistamines or beta-blockers are usually taken only when needed for anxiety, or 
immediately before an anxiety-provoking event (for example, taking propranolol 
shortly before giving a speech). Finally, certain anticonvulsant medicines, such as 
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gabapentin (Neurontin) and pregabalin (Lyrica), are also beginning to show value in 
treating some forms of anxiety in initial research studies acute anxiety. The most 
prominent of anti-anxiety drugs for the purpose of immediate relief are those known 
as benzodiazepines; among them are alprazolam (Xanax), clonazepam (Klonopin), 
chlordiazepoxide (Librium), diazepam (Valium), and lorazepam (Ativan). They have 
drawbacks: Benzodiazepines sometimes cause drowsiness, irritability, dizziness, 
memory and attention problems, and physical dependence. Nonetheless, in recent 
decades they have largely replaced barbiturates because they tend to be safer if taken 
in large doses. 
Another anti-anxiety drug is busprirone (Buspar). It has fewer side effects than 
the benzodiazepines and is not associated with dependence. Buspar, however, can 
have its own side effects and may not always be as effective when a person has taken 
benzodiazepines in the past. 
Cognitive behavioural therapy: 
Cognitive behavioural therapy (CBT) is based on evidence that shows that 
persons with generalized anxiety disorder (GAD) engage in overestimations and 
catastrophizing of negative events; show limited confidence in problem solving; 
require additional evidence before making decisions; have a low tolerance of 
uncertainty, an iterative problem-solving style, worry about worry, and numerous 
behavioral and cognitive strategies that may actually be counterproductive and help 
maintain the self-perpetuating cycle of worry. 
Specific techniques:  CBT is a multimodal intervention for GAD, including 
patient education, self-monitoring, relaxation training, cognitive restructuring, 
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imagery exposure, exposure to anxiety provoking situations, and relapse prevention. 
These techniques are described below. 
Education — Treatment begins with education on: 
 Informing and correcting misconceptions regarding anxiety, worry, and 
associated symptoms 
 Causative factors of pathological worry and anxiety 
 A model of factors that perpetuate GAD 
 The treatment plan and rationale (ie, symptoms of GAD will subside by using 
evidence-based and coping oriented thinking, by dealing directly with anxiety 
provoking images and situations, and by learning to relax) 
Much of this information is integrated in presenting how a pathological cycle 
of worry and anxiety develops and is maintained in patients’ lives. 
Self-monitoring: Self-monitoring is introduced in the first treatment session 
and continues throughout the entire treatment. Learning to observe their reactions 
from an objective standpoint encourages the patient’s development as a personal 
scientist and increases his or her accuracy in self-observation. Self-monitoring allows 
patients to chart their progress in therapy. 
Relaxation training: Relaxation training can be particularly meaningful for 
GAD patients as they often experience elevated muscle tension and reduced flexibility 
of autonomic functioning. Relaxation training consists of progressive muscle 
relaxation (after brief deliberate tension) of all muscle groups of the body in a 
systematic manner, beginning with 16 muscle groups, and then condensing to 8 
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muscle groups, and 4 muscle groups. Relaxation training ends with cue-control 
relaxation, where patients cue themselves to relax by simply repeating a word (such as 
“relax”) that has been repeatedly paired with relaxation phases during the preceding 
weeks of progressive muscle relaxation training. Cue-control relaxation is then used 
as a coping skill for practicing exposure to anxiety-producing images or situations 
(also referred to as “applied relaxation”). Breathing exercises, such as slow, 
diaphragmatic breathing, may be incorporated into relaxation training. 
Cognitive restructuring: Cognitive restructuring is a set of skills for identifying and 
modifying misappraisals that contribute to anxiety, including: 
 Patients are shown how anxiety and maladaptive behaviors are generated by 
overly-negative interpretations of events. 
 Patients are helped to identify errors in thinking (eg, overestimating the 
probability or valence of negative events) and rigid rules or beliefs that 
underlie dysfunctional thought patterns. 
 Patients are encouraged to use an empirical approach to examine the validity 
of thoughts by considering all of the available evidence. 
Therapists use Socratic questioning to help patients make guided discoveries 
and question their anxious thinking. Patients then generate alternative interpretations 
or “hypotheses” to situations with the help of additional evidence gathered in 
behavioral practices in anxiety-provoking situations. As an example, a person who 
typically avoided taking on new responsibilities due to worries about making mistakes 
was encouraged to take on new responsibilities, to gather evidence on what happens 
subsequently. He or she learned that mistakes were less frequent than anticipated and 
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did not have negative consequences. Underlying beliefs (eg, “I am incompetent”) are 
postulated to change with the patient’s accrual of evidence that challenges his or her 
negative thoughts. 
Imagery exposure: Imagery exposure is designed to help patients tolerate 
negative affect and autonomic arousal associated with fearful images that they often 
attempt to avoid through worry. Patients generate hierarchies of fear images related to 
two or three main areas of worry and are led through systematic exposure to these 
images. When anxiety elicited by an image is reduced to a mild level, then patients 
progress to the next image on the hierarchy. Two main versions of imagery exposure 
have been developed 
 In one version, patients imagine a worst case scenario for 25 to 30 minutes, and 
then generate alternative outcomes to the scenario. This approach has been shown 
to be effective for GAD as a standalone treatment in a small randomized trial. 
 The second version, self-controlled desensitization, involves utilization of 
cognitive restructuring and relaxation skills during imagery exposure to anxiety-
provoking situations. It has been incorporated into CBT in a number of studies. 
Exposure to anxiety-provoking situations: This technique involves repeated 
exposure to situations that are avoided or engaged in with excessive preparation or 
checking. Patients generate a hierarchy of situations or activities. Examples include 
allowing children to have sleep overs, family vacations, arriving on time (instead of 
excessively early) at scheduled appointments, taking on responsibilities, or saying 
‘no’ to requests. Patients rehearse cognitive restructuring and relaxation coping skills 
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in session. Subsequently, they practice using these techniques to manage anxiety in 
situations that occur between sessions. 
Relapse prevention : A final step in CBT is relapse prevention, in which 
patients are informed that recurrences of worry, anxiety or avoidance behavior are 
likely to occur in the future. They are encouraged to view such recurrences as lapses 
rather than failure, and to reapply their coping skills and reinstitute their practice of 
exposure to images of negative outcomes and anxiety-provoking situations. 
Psychodynamic therapy:  
In psychodynamic approaches to GAD, treatment typically focuses upon core 
conflictual relationship themes. Emphasis is placed upon a positive therapeutic 
alliance to provide a corrective emotional experience to offset insecure attachment. 
Emotional regulation therapy:  Emotional regulation therapy incorporates 
components of CBT such as psychoeducation and self-monitoring, as well as 
interventions that address emotion regulation (deficits prominent in GAD), emotional 
avoidance, and interpersonal difficulties.  
Mindfulness: Mindfulness involves the non-judgmental observation of moment to 
moment experiences. Acceptance and Commitment Therapy combines mindfulness 
with acceptance of internal states and orientation of actions towards valued goals. 
Although there are some similarities between an ACT approach and a CBT approach, 
ACT does not involve any form of cognitive restructuring (ie, identifying, 
challenging, and replacing negative thinking with more realistic thinking) or any 
attempt to change or correct somatic dysregulation (eg, relaxation training). A 
randomized clinical trial compared ACT to applied relaxation in patients with GAD.  
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REVIEW OF LITERATURE 
Aaron M Eakman et al (2017)13 
They conducted a pilot study on restoring effective sleep tranquillity (REST). 
The participants were United States post-9/11 veterans with service-connected 
injuries, university students, and had self-reported sleep disturbances. REST was a 
multi-component cognitive behavioural therapy for insomnia intervention consisting 
of seven sessions of group therapy and eight 1:1 sessions delivered by occupational 
therapists. Indicators were supportive of feasibility, including reduced sleep 
difficulties, reduced nightmares, fewer dysfunctional sleep beliefs and greater ability 
to participate in social roles, along with trends towards improved satisfaction with 
participation and reduced pain interference.  
ZubiaVeqar et,. Al (2014)70 
The purpose of this study was to establish test- retest reliability, validity and 
internal consistency of Pittsburgh insomnia rating scale among Indian population. 
Twenty five subjects were randomly chosen from the screened population of poor 
sleepers. The study findings suggest that Pittsburgh insomnia rating scale has 
excellent internal consistency, test-retest reliability and good validity for university 
population of poor sleepers in India. It is an important first line of assessment scale 
for screening of sleep problems. 
Christi S. Ulmer et,.al (2011)26 
They conducted a pilot study on Multi-Component Cognitive-Behavioral 
Intervention for Sleep Disturbance in Veterans with PTSD. They included twenty-two 
veterans for the study, The findings demonstrate that an intervention targeting trauma-
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specific sleep disturbance produces large short-term effects, including substantial 
reductions in PTSD symptoms and insomnia severity. 
Yong Woo Kim et,. Al (2009)68 
The objective of his study was to examine the effectiveness of newly 
developed Mindfulness-based cognitive therapy program as an adjuvant to 
pharmacotherapy in the treatment of patients with panic disorder or generalized 
anxiety disorder. Patients with panic disorder or generalized anxiety disorder were 
assigned to either MBCT or an anxiety disorder education (ADE) program for a 
period of 8 weeks. As a result the obsessive-compulsive and phobic subscales showed 
significantly more improvement in the Mindfulness-based cognitive therapy group. 
However, no significant improvement was observed in the Mindfulness-based 
cognitive therapy group versus the anxiety disorder education group in terms of the 
somatization, interpersonal sensitivity, paranoid ideation, or psychoticism subscale 
scores. 
Jason C. Ong (2008)40 
This study was designed to evaluate the efficacy of mindfulness meditation for 
the treatment of chronic insomnia. It was a randomized controlled trial with fifty-four 
adults with chronic insomnia. The result of the study suggests that mindfulness 
meditation appears to be a viable treatment option for adults with chronic insomnia 
and could provide an alternative to traditional treatments for insomnia. 
Dag Neckelmannet.al.,(2007)28 
This study was aimed to find out the relationship of insomnia to the 
development of anxiety disorders and depression in a population-based sample. They 
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have done a Cohort study based on data from two general health surveys of the adult 
population. After analysing the data it was prominent that insomnia may be a trait 
marker for individuals at risk for developing anxiety disorders. 
Daniel J. Taylor, et al (2007)29 
The study was aimed to determine the comorbidity of insomnia with medical 
problems. A Cross-sectional and retrospective study was conducted with Community-
based population of 772 men and women, aged 20 to 98 years old. This study 
demonstrates significant overlap between insomnia and multiple medical problems, 
the study also suggest that people with insomnia had greater depression and anxiety 
levels than people not having insomnia and were 9.82 and 17.35 times as likely to 
have clinically significant depression and anxiety, respectively. 
BørgeSivertsen, et al (2006)19 
The study was aimed to examine short- and long-term clinical efficacy of 
cognitive behavioural therapy (CBT) and pharmacological treatment in older adults 
experiencing chronic primary insomnia. The study was a randomized, double-blinded, 
placebo controlled trial of 46 adults, outcome of this study suggest that interventions 
based on CBT are superior to zopiclone treatment both in short- and long-term 
management of insomnia in older adults. 
Andrew Green et al (2005)15 
The study was A Cognitive-Behavioural Group Intervention for People with 
Chronic Insomnia, the nonpharmacological management of chronic insomnia led to 
the establishment of a treatment group in which occupational therapists have been 
involved. The outcome data from seven groups are presented. Sleep diaries indicate a 
 27 
modest improvement in total sleep time, with further improvement at 3-month follow-
up. Participant feedback shows that people with insomnia value expert advice and 
support as well as meeting others with similar problems.  
Catherine D. Jefferson (2005)23 
This study was designed to assess selected aspects of sleep hygiene from a 
population-based sample of individuals with insomnia compared to age- and sex-
matched controls. They included a population of 258 individuals with age group of18 
to 65 years. The study suggest that insomniacs do engage in specific poor sleep 
hygiene practices, such as smoking and drinking alcohol just before bedtime. These 
particular aspects of sleep hygiene may be important components that exacerbate or 
perpetuate insomnia. 
Ce´lyne H. Bastienet al (2004)24 
This study was designed to compare the effect CBT delivered through 
Individual Therapy, Group Therapy, and Telephone Consultations. They give CBT 
for Forty-five adults with primary insomnia and found out that CBT was effective in 
improving sleep parameters with all 3 methods of treatment implementation, and there 
was no significant difference across methods of implementation. 
Maurice M etal (2001)42 
The study was designed to determine the role of activity status and social life 
satisfaction on the report of insomnia symptoms and sleeping habits. The study used a 
large population of  13,057  subjects age 15 and older. In this study they found out 
that Insomnia symptoms were reported by more than one-third of the population age 
65 and older. Multivariate models showed that age was not a predictive factor of 
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insomnia symptoms when controlling for activity status and social life satisfaction. 
The level of activity and social interactions had no influence on napping, but age was 
found to have a significant positive effect on napping. 
Colin A. Espie et al (2001)27 
This study specifically investigated the clinical effectiveness of CBT delivered 
by Health Visitors (primary care nurses) trained as therapists. One hundred and thirty-
nine insomniacs (mean age 51 yr) were randomised to CBT or Self-Monitoring 
Control (SMC) in a controlled trial. Superiority of CBT over SMC in substantially 
reducing sleep latency and wakefulness during the night. CBT-DEF replicated similar 
effects and maintained improvement was observed in both groups one year later. 
Furthermore, total sleep increased significantly during follow-up and 84% of patients 
initially using hypnotics remained drug-free. Results suggest that CBT administered 
by Health Visitors offers a clinically effective treatment for insomnia. 
Spielmanetal (1987)63 
In this study they assigned thirty-five patients, with a mean age of 46 years 
and a mean history of insomnia of 15.4 years. And were treated initially by marked 
restriction of time available for sleep, followed by an extension of time in bed 
contingent upon improved sleep efficiency, At the end of the 8-week treatment 
program, patients reported an increase in total sleep time as well as improvement in 
sleep latency, total wake time, sleep efficiency, and subjective assessment of their 
insomnia. Improvement remained significant for all sleep parameters at a mean of 36 
weeks after treatment in 23 subjects participating in a follow-up assessment. 
 
 29 
Robin puderetal (1983)56 
This study was designed to find out Short-Term Stimulus Control Treatment 
of Insomnia in Older Adults. They did a 4-week stimulus control treatment to 16 
ambulatory, noninstitutionalized older adults with sleep onset insomnia of which nine 
subjects received immediate treatment, and 7 received delayed treatment. This study 
confirms that short-term stimulus control therapy is effective in decreasing sleep-
onset among insomnia in older adults. 
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Occupational therapy intervention + 
conventional therapy 
 
Conventional Therapy only 
METHODOLOGY 
STUDY DESIGN: 
Quasi Experimental Design.  
Experimental group  
Pre-test           Post test 
Control group : 
Pre-test         post test 
SAMPLE SIZE 
Total consecutive samples of 30 subjects were taken for this study. The 
subjects were divided into two groups as experimental and control group. The control 
group consist of 15 subjects, and experimental group consist of 15 subjects. 
Table 1 
Group AGE 
SEX 
Male Female 
Control Group Mean: 32.2 9 6 
Experimental Group Mean: 32 10 5 
 
SAMPLING TECHNIQUE 
Convenient sampling technique was adopted. 
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STUDY PLACE 
Vivekananda Health Centre, Erode. 
DURATION OF THE STUDY 
Duration of the study is one year 
SELECTION CRITERIA 
Inclusion criteria 
 Participants with Insomnia between ages 20 to 45 years. 
 Participants with onset of illness from 3months to 1 year. 
 Both male and females 
 Participants should able to read and understood Basic English language.  
 Participants who score 18 or more in HAM-A 
Exclusion criteria 
 Age should not be more than 45 and less than 20 years 
 Participants with other mental illness  
 Participants with other medical illness  
VARIABLES 
Independent Variables 
 Occupational therapy activities. 
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Dependent Variables 
 Insomnia 
MEASUREMENT TOOLS / MATERIALS USED 
The tools used for the study is Pittsburgh insomnia rating scale and Hamilton 
Anxiety Scale. 
DESCRIPTION OF THE INSTRUMENT  
Pittsburgh insomnia rating scale: it is a 65 item self-administered open 
source questionnaire. PIRS is a widely used instrument in clinical and research 
practice. It is a scale with 65-items. It was designed to rate the severity of insomnia. 
Subjects score the items that have three broad sections.  
1. Distress score (46 items) 
2. Sleep parameters (10 items) 
3. Quality-of-life (9 items). 
Section A of the scale has a 10 cm line to mark the quality of sleep in the past 
week. This answer is not used in the scoring.70 
Section B has 46 questions which have to be answered on the likert scale from 0-3  
 0 = not at all bothered,  
 1 = slightly bothered,  
 2 = moderately bothered,  
 3 = severely bothered. 
 33 
Section C has 10 questions which have to be answered on the likert scale 0-3 
with variable answers depending on the question. Score of this section is the addition 
of all and is termed as sleep parameters score. Section D has 9 questions which have 
to be answered on the likert scale from 0-3 
 0 = excellent,  
 1 = good,  
 2 = fair,  
 3 = poor.  
Addition of all the answers gives the final score which is termed as Quality of 
life score. Section E is about comments which the patient wants to put in but it is not 
included in the scoring. Final score is the grand total of all the three components. 
Minimum score is 0 (good) and maximum is 195 (bad). 
Reliability & Validity 
The retest reliability for PIRS total score was 0.93 which indicates excellent 
reliability. Distress score ICC2 was 0.90 which indicates excellent reliability. Sleep 
parameters score ICC2 was 0.70 which indicates a good reliability. Quality of life 
score ICC2 was 0.71 which indicates a good reliability. 
Concurrent validity: moderately positive correlation between PSQI and PIRS 
(r-0.31 P value-0.13), moderately positive correlation between PIRS and ISI (r-0.49 P 
value-0.012). 
Internal consistency: Cronbach’s alpha coefficient was calculated for Total 
PIRS score (α-0.93) which indicates excellent internal consistency. Component 
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score’s Cronbach’s alpha coefficient are- Distress score (α-0.82), Sleep parameters 
score (α-0.70) and Quality of life score (α-0.71) which is an acceptable internal 
consistency. 
Homogeneity: PIRS total score to component scores ranged from high to 
moderately correlated positive relationship(r’s-0.96 to 0.37) correlations between 
individual items and total score ranged from 0.07 to 0.96. 
THE HAMILTON ANXIETY SCALE: 
The HAM-A was one of the first rating scales developed to measure the 
severity of anxiety symptoms, and is still widely used today. The scale consists of 14 
items, each defined by a series of symptoms, and measures both psychic anxiety 
(mental agitation and psychological distress) and somatic anxiety (physical 
complaints related to anxiety). 
Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range 
of 0–56, where 
 14-17 = Mild Anxiety 
 18-24 = Moderate Anxiety 
 25-30 = Severe Anxiety 
Reliability&Validity 
The interrater reliability of HAM-A total score: 0.74; HAM-A total score of 
psychic anxiety: 0.73; HAM-A total score of somatic anxiety: 0.70. Items 10 
(respiratory symptoms), 14 (behaviour at interview) and 13 (autonomic symptoms) 
had the lowest reliability (lower than 0.30). Concurrent validity of the HAM-A Total 
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scale score 0.75, Total subscale score (psychic anxiety) 0.80, Total subscale score 
(somatic anxiety) 0.85. 
PROCEDURE 
A total of 30 subjects were taken for this study.  The subjects were selected 
from the age group between 20 to 45 years, already diagnosed as Insomnia and 
anxiety by a psychiatrist.Individuals who meets the selection criteria has been 
administrated with Hamilton Anxiety Rating Scale.  Individual who score more than 
18 in HAM-A are then selected and importance of the study has explained to them 
and obtained consent form each subjects. The subject then divided in to two groups; a 
control group and an experimental group, the control group consist of 15 subjects and 
also the experimental group, all the subjects were taken from Vivekananda health 
centre Erode. 
The control group received only conventional therapies were as experimental 
group underwent occupational therapy intervention along with conventional therapy. 
Pre- test was conducted in both groups before the intervention with using Pittsburgh 
Insomnia Rating Scale 
SESSIONS 
The intervention spanned a period of eight weeks. Of these, there were seven 
weeks in which group occupational therapy sessions scheduled for participant along 
with 1:1 session (weeks 1, 2, 3, 4, 5, 6, and 8). Only 1:1 occupational therapy sessions 
were scheduledfor the remaining week (week 7). A group intervention approach was 
adopted for a principle reasons. A group intervention can be therapeutic via 
establishing the cohesiveness of the group, instilling hope, and allowing for 
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interpersonal learning.30 Therefore, a group approach could allow for the development 
of a sense of comradery and peer support throughout program delivery. Secondly, 
group has demonstrated promise as an effective method for treating insomnia 
comorbid with mental health conditions .30The 1:1 occupational therapy was included 
within this because 1:1 intervention is the gold standard in the delivery treatment for 
chronic insomnia.33 
Table 2 
SESSIONS CONTENT 
1 
Didactic education about: 
1. Sleep architecture 
2. Importance of sleep 
3. Insomnia 
2 
Meditation: 
1. Relaxation training 
2. Mindful walking 
3. Body scan 
3 
Stimulus control: 
1. Association of bed with sleep.  
2. If in bed for more than 10-15 minutes not sleeping, get out of bed, 
go to another room and do something enjoyable.Go back to bed 
only when sleepy. 
3. No clock-watching. 
4. Get out of bed within five minutes of alarm sounding. 
4 
Sleep Restriction Therapy (SRT) 
1. Wake up at the same time every day (Decided together). 
2. Go to bed at the same time every night. (Decided by occupational 
therapist based on average sleep diary data.) 
3. No naps. 
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5 
Sleep Hygiene 
1. Keep room cool (20 degrees), quiet, and dark. 
2. Limit alcohol and caffeine. 
3. Quit using nicotine. 
4. Exercise and eat healthy. 
5. Keep daytime routine consistent. 
6. Stay active/engaged throughout the day. 
6 
CBT: 
1. Cognitive Restructuring 
7 
Individual session :addressing  
1. Personal factors 
2. Beliefs 
3. Goal setting around stimulus control and sleep hygiene 
4. Calculation of SE= (TST/TIB)×100 
8 Role-Playing: 
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DATA ANALYSIS AND INTERPRETATION 
 
Table 3 : Pittsburgh insomnia rating scale 
Subjects 
Control group Experimental group 
Pre test Post test Pre test Post test 
1.  163 76 141 36 
2.  162 90 156 74 
3.  164 61 150 40 
4.  158 67 149 30 
5.  176 66 153 62 
6.  165 64 161 51 
7.  170 78 146 86 
8.  163 149 175 76 
9.  155 107 159 94 
10.  147 107 175 61 
11.  129 111 173 54 
12.  135 112 163 66 
13.  171 123 168 105 
14.  125 109 161 55 
15.  156 120 180 54 
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COMPARISON OF PRE TEST BETWEEN CONTROL AND 
EXPERIMENTAL GROUP 
Table 4 
Sl. 
No. 
PIR Mean 
Std. 
Error of 
Mean 
S.D 
“t” 
Value 
“p” 
Value 
1 Pre-test (control) 155.9 3.974 15.39 
0.9468 P>0.05 
2 Pre-test (experimental) 160.7 3.033 11.75 
 
Graph 1 
 
Table 4 shows that comparison between the control group Pre-test and 
experimental group Pre-test score mean values155.9;160.7 “t” values 0.9468 and “p” 
values 0.3518 which is greater than acceptance levels of significance of 0.05 so it is 
not statistically significant. 
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COMPARISONBETWEENPRE AND POST TESTSOF CONTROL GROUP 
Table 5 
Sl. 
No. 
PIR Mean 
Std. 
Error of 
Mean 
S.D 
“t” 
Value 
“p” 
Value 
1 Pre-test 155.9 3.974 15.39 
6.596 P<0.05 
2 Post-test 96 6.816 26.4 
 
Graph 2 
 
Table 5 shows that comparison between the control group pre-test and post 
test score mean values 155.9; 96 and “t” value 6.596 and “p” value which is Less than 
acceptance level of significance of 0.05. Hence  it is statistically significant. 
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COMPARISON BETWEEN PRE AND POST TEST OF EXPERIMENTAL 
GROUP 
Table 6 
Sl.No. PIR Mean 
Std. 
Error of 
Mean 
S.D 
“t” 
Value 
“p” 
Value 
1 Pre-test 160.7 3.033 11.75 17.72 P<0.05 
2 Post-test 62.93 5.466 21.17 
 
Graph 3 
 
 
 
 
 
 
 
Table 6 shows that comparison between the experimental group pre-test and 
post test score mean values 160.7; 62.93and “t” values 17.72and “p” values which is 
less than acceptance level of significance of 0.05. Hence it is extremely statistically 
significant. It shows that experimental group has significant improvement. 
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COMPARISON BETWEEN POST TESTS OF CONTROL AND 
EXPERIMENTAL GROUP 
Table 7 
Sl. 
No. 
PIR Mean 
Std. 
Error of 
Mean 
S.D 
“t” 
Value 
“p” 
Value 
1 Post-test (control) 96 6.816 26.4 
3.785 P<0.05 
2 Post-test (experimental) 62.93 5.466 21.17 
 
Graph 4 
 
Table 7 shows that comparison between the control group post-test and 
experimental group post test score mean values 96; 62.93 “t” values 3.785 and “p” 
values which is less than acceptance levels of significance of 0.05. Hence it is 
statistically significant. It shows that experimental group has more improvement than 
that of control group. 
25
35
45
55
65
75
85
95
105
Control Group
Experimental Group
POST-TEST 
 43 
  DISCUSSION 
 
Sleep disturbance is a clinical feature of nearly all psychiatric conditions and 
sleep is disrupted by symptoms of many physical conditions. Poor sleep totally affect 
the day time functioning of the person which leads to further complications. 
Occupational therapists could take a greater part in managing the sleep difficulties of 
their patients. It is proposed that from a more practical perspective there is a strong 
argument that they are well placed to assume a positive role. The purpose of this study 
is to find out effect of occupational therapy intervention in insomnia among person 
with anxiety. 
 The subjects for this study have been taken from Vivekananda health centre, 
individuals who meets the selection criteria has been administrated with Hamilton 
Anxiety Rating Scale. Individual who score more than 18 in HAM-A are invited to 
participate in the study and importance of the study has explained to them. Among 
those who was willing to participate in the study, consent form has taken and kept a 
cut off total 30 subjects as maximum sample size. Then the selected subjects has been 
allocated in two groups consist of 15 in each. The mean age of control group was 32.2 
and 32 in Experimental group.   Pre-test was done using Pittsburgh Insomnia Rating 
Scale after the pre-test experimental group received occupational therapy intervention 
for eight weeks along with conventional therapy and medication, whereas control 
group only receive conventional therapy and medication. After which a post- test was 
conducted using the same scale. 
Unpaired ‘t’-test has been calculated for the both experimental and control 
group (Table 4). The mean of pre-test was found to be 155.9 (control) and 160.7 
 44 
(experimental) respectively. The calculated ‘t’ value was obtained (0.9468) with 
confidence level of 95%, P>0.05 which indicates there is no significant difference  
between both experimental and control group. Hence shows the homogeneity of the 
allocated subjects.  
Paired ‘t’ test has been calculated for the control group (Table 5).  The mean 
of pre-test was found to be155.9 and the post test was 96. The calculated ‘t’ value was 
obtained to be 6.596 with level of significance 0.05. Hence the table ‘t’ value is less 
than calculated ‘t’ value, which indicate  significant difference between pre and post-
test values. 
This study did not include an active control condition thus, we cannot 
determine the effect of nonspecific factors, such as treatment expectancies and 
therapeutic alliance, socio economic factors and cultural influence. 
Paired‘t’ test have been calculated for the experimental group (Table 6).  The 
mean of pre test was found to be 160.7 and the post test was 62.93. The calculated ‘t’ 
value was obtained to be 17.72 with level of significance 0.05. Hence the table‘t’ 
value is less than calculated ‘t’ value. So there is extremely significant difference 
between pre and post-test values. 
This is supported by Christi S. Ulmer etal (2011)26 their study was Multi-
Component Cognitive-Behavioural Intervention for Sleep Disturbance in Veterans 
with posttraumatic stress disorder and the subjects were twenty-two veterans. The 
findings demonstrate that an intervention targeting trauma-specific sleep disturbance 
produces large short-term effects, including substantial reductions in PTSD symptoms 
and insomnia severity. 
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Unpaired ‘t’ test has been calculated for the both experimental and control 
group (Table 7).  The mean of post-test was found to be 96 (control) and 62.93 
(experimental) respectively. The calculated‘t’ value was obtained to be 3.785 with 
level of significance 0.05. Hence the table‘t’ value is less than calculated ‘t’ value. So 
there is a significant difference between both group means, which leads to the 
rejection of null hypothesis. 
This is supported by Aaron M Eakman et al (2017)13 they conducted a pilot 
study on restoring effective sleep tranquillity (REST). REST was a multi-component 
cognitive behavioural therapy for insomnia intervention consisting of seven sessions 
of group therapy and eight 1:1 sessions delivered by occupational therapists. The 
indicators were supportive of feasibility, including reduced sleep difficulties, reduced 
nightmares,fewer dysfunctional sleep beliefs and greater ability to participate in social 
roles, along with trends towards improved satisfaction with participation and reduced 
pain interference. 
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CONCLUSION 
 
The result of this study indicates that person who had occupational therapy 
intervention shows more improvement than who had conventional therapy. Therefore 
occupational therapy technique considered as a therapy intervention for Insomnia.  
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LIMITATION AND RECOMMENDATIONS 
LIMITATION 
 Study was done on a small sample size. 
 Study was conducted in confined geographical location. 
 Male and female comparison is not included in this study. 
 Study was done on confined age group between 20 to 45 yrs 
RECOMMENDATIONS 
 The study can be done with other coexisting conditions. 
 Study can be done by using electronic sleep monitoring devices.  
 The study can be done by translating the scale into local language. 
 Based on this study it is recommended to use occupational therapy interventions 
for person with insomnia. 
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MASTER CHART 
Subject 
code Age Sex 
Pittsburgh Insomnia 
Rating Scale HAM-A 
Pre-test Post-test 
1.  38 M 141 36 26 
2.  43 M 156 74 34 
3.  30 M 150 40 30 
4.  40 F 149 30 27 
5.  32 F 153 62 36 
6.  22 M 161 51 34 
7.  29 F 146 86 30 
8.  31 F 175 149 39 
9.  29 F 159 107 28 
10.  28 M 175 107 34 
11.  27 M 173 111 41 
12.  38 M 163 112 32 
13.  41 M 168 123 30 
14.  29 M 161 109 23 
15.  27 F 180 120 40 
16.  32 F 163 76 29 
17.  30 F 162 90 32 
18.  41 F 164 61 35 
19.  34 F 158 67 30 
20.  28 F 176 66 34 
21.  39 M 165 64 26 
22.  36 M 170 78 47 
23.  29 M 163 76 34 
24.  43 M 155 94 29 
25.  29 M 147 61 27 
26.  26 M 129 54 23 
27.  29 M 135 66 24 
28.  27 F 171 105 42 
29.  28 M 125 55 19 
30.  29 M 156 54 25 
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CONFIDENTIALITY 
Your name will not be associated with the results in this study. It will be 
issued for both teaching and research purpose. Only myself and my guide will have 
access to the name of the subjects participating in this study. 
The following is the name address and telephone number of the person to be 
contacted in event of research related inquiry. 
Name   : Richu Joseph 
Address : JKKMMRF College of Occupational Therapy 
  Komarapalayam, Namakkal Dt. 
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VOLUNTARY CONCERN FORM 
NAME                                     : 
AGE                                        : 
SEX                                         : 
ADDRESS FOR COMMUNICATION    : 
 
DECLARATION 
 I have fully understood the nature and purpose of the study. I have understood 
that I have the right to withdraw from this study at any point of time without 
adversely affect my treatment. I have read this consent form and accept to be a subject 
in this study on my own accord. I declare that the above information is true to my 
knowledge. 
    
Signature of the informant 
Date:  
Place:   
 
